Evaluation of 28 cases of mucormycosis

Mycoses

Volumn 58, Issue 2, 2015, Pages 82-87

  Kursun, Ebru ^a   Turunc, Tuba ^a   Demiroglu, Yusuf Ziya ^a   Alişkan, Hikmet Eda ^a   Arslan, Ayşe Hande ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Diagnosis; Mucormycosis; Orbital apex syndrome; Posaconazole

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN INFECTION; CHILD; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONSCIOUSNESS DISORDER; CRANIAL NEUROPATHY; DEMOGRAPHY; DIABETES MELLITUS; DIPLOPIA; DISEASE PREDISPOSITION; ENDOSCOPIC SINUS SURGERY; EVISCERATION; FACE PAIN; FACIAL NERVE PARALYSIS; FEMALE; FEVER; FOLLOW UP; HEADACHE; HEMATOLOGIC MALIGNANCY; HUMAN; LABORATORY TEST; MALE; MIDDLE AGED; MUCORMYCOSIS; MYDRIASIS; NOSE INFECTION; NOSE OBSTRUCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOPLEGIA; ORBIT CELLULITIS; ORBIT INFECTION; OUTCOME ASSESSMENT; PERIORBITAL EDEMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VISUAL IMPAIRMENT; COMPLICATION; DIABETES COMPLICATIONS; DRUG EFFECTS; EPIDEMIOLOGY; HEMATOLOGIC DISEASE; MUCORALES; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CAUSALITY; CHILD; DIABETES COMPLICATIONS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MUCORALES; MUCORMYCOSIS; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84921534385     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12278     Document Type: Article

References (28)

1. Kume H, Yamazaki T, Abe M, Tanuma H, Okudaira M, Okayasu I. Increase in aspergillosis and severe mycotic infection in patients with leukemia and MDS: comparison of the data from the Annual of the Pathological Autopsy Cases in Japan in 1989, 1993 and 1997. Pathol Int 2003; 53: 744-50.
2. Abidi MZ, Sohail MR, Cummins N et al. Stability in the cumulative incidence, severity and mortality of 101 cases of invasive mucormycosis in high-risk patients from 1995 to 2011: a comparison of eras immediately before and after the availability of voriconazole and echinocandin-amphotericin combination therapies. Mycoses 2014; 57: 687-98.
3. Chamilos G, Luna M, Lewis RE et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006; 91: 986-9.
4. Sundaram C. Rhinocerebral Zygomycosis - a clinicopathological study. Neurol India 1998; 46: 126-9.
5. Demiroğlu YZ, Turunc T, Erkan AN, Alkan Ö, Alişkan HE, Arslan H. Rhinocerebral mucormycosis treated with posaconazole: a case report. Klimik Dergisi 2010; 23: 130-3.
6. Khor BS, Lee MH, Leu HS, Liu JW. Rhinocerebral mucormycosis in Taiwan. J Microbiol Immunol Infect 2003; 36: 266-9.
7. Nithyanandam S, Jacob MS, Battu RR, Thomas RK, Correa MA, D'Souza O. Rhino-orbito-cerebral mucormycosis. A retrosepective analysis of clinical features and treatment outcomes. Indian J Ophthalmol 2003; 51: 231-6.
8. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
9. Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect 2004; 10: 31-47.
10. Cornely OA, Arikan-Akdagli S, Dannaoui E et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect 2014; 20(Suppl. 3): 5-26.
11. Bitar D, Van Cauteren D, Lanternier F et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis 2009; 15: 1395-401.
12. Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population-based laboratory active surveillance. Clin Infect Dis 1998; 27: 1138-47.
13. Torres-Narbona M, Guinea J, Martínez-Alarcón J, Peláez T, Bouza E. In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre Yeast One, and the Etest. Antimicrob Agents Chemother 2007; 51: 1126-9.
14. Sugar AM. Agents of mucormycosis and related species. In: Mandell GL, Bennett JE, Dolin R (eds), Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, 6th edn. Philadelphia, PA: Churchill Livingstone, 2005: 2973-84.
15. Wali U, Balkhair A, Al-Mujaini A. Cerebro-rhino orbital mucormycosis: an update. J Infect Public Health 2012; 5: 116-26.
16. Skiada A, Pagano L, Groll A et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011; 17: 1859-67.
17. Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634-53.
18. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350: 950-2.
19. Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother 2007; 51: 2587-90.
20. Schlemmer F, Lagrange-Xelot M, Lacroix C, de La Tour R, Socie G, Molina JM. Breakthrough Rhizopus infection on posaconazole prophylaxis following allogeneic stem cell transplantation. Bone Marrow Transplant 2008; 42: 551-2.
21. Tacke D, Koehler P, Markiefka B, Cornely OA. Our 2014 approach to mucormycosis. Mycoses 2014; 57: 519-24.
22. Lackner M, Caramalho R, Lass-Flörl C. Laboratory diagnosis of mucormycosis: current status and future perspectives. Future Microbiol 2014; 9: 683-95.
23. Kishel JJ, Sivik J. Breakthrough invasive fungal infection in an immunocompromised host while on posaconazole prophylaxis: an omission in patient counseling and follow-up. J Oncol Pharm Pract 2008; 14: 189-93.
24. Zeka AN, Tasbakan M, Pullukcu H, Sipahi OR, Arda B. Evaluation of zygomycosis cases by pooled analysis method reported from Turkey. Mikrobiol Bul 2003; 47: 708?16.
25. Turan MN, Tatar E, Yaprak M et al. A mucormycosis case presented with orbital apex syndrome and hemiplegia in a renal transplant patient. Int Urol Nephrol 2013; 45: 1815-9.
26. Zaoutis TE, Roilides E, Chiou CC et al. Mucormycosis in children: a systematic review and analysis of reported cases. Pediatr Infect Dis J 2007; 26: 723-7.
27. Cornely OA, Vehreschild JJ, Rüping MJ. Current experience in treating invasive zygomycosis with posaconazole. Clin Microbiol Infect 2009; 15: 77-81.
28. Tobón AM, Arango M, Fernández D, Restrepo A. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin Infect Dis 2003; 36: 1488-91.